Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
KEYWORDS: people, treatment, anticoagulation, dvt, committee, anticoagulation treatment, evidence, vte, recommendations, risk, cancer, agreed, clinical, use, d-dimer

evidence and the committee's discussion are in evidence review D: pharmacological treatment in people with suspected or confirmed DVT and/or PE. 7 Predicting VTE recurrence and major bleeding What is the prognostic accuracy of a tool to predict both VTE recurrence and major bleeding after 3 months of initial anticoagulation treatment and in the long term? [2020] For a short explanation of why the committee made the recommendation for research, see the rationale section on long-term anticoagulation for secondary prevention. Full details of the evidence and the committee's discussion are in evidence review F: what factors determine the optimum duration of pharmacological treatment for DVT or PE in people with a VTE? 8 Thrombolytic therapy for DVT What is the clinical and cost effectiveness of clot removal using catheter-directed thrombolytic therapy or pharmacomechanical thrombolysis compared with standard anticoagulation therapy for the treatment of acute proximal DVT? [2012] Rationale and impact These sections briefly explain why the committee made the recommendations and how they might affect practice. They link to details of the evidence and a full description of the committee's discussion. Diagnosis and initial management in people with COVID-19 Recommendations 1.1.1 to 1.1.22 Why the committee made the recommendations The
